A prospective study of xenon arc photocoagulation for central retinal vein occlusion.

May, Donald R.; Klein, Michael L.; Peyman, Gholam A.

doi:10.1136/bjo.60.12.816

Cited by 18 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of this study are in accordance with the preliminary results reported by May et al (1976). In their randomised study on 20 eyes (10 treated, 10 untreated) 2 cases of neovascular glaucoma were found in the untreated group and none in the treated group.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Panretinal photocoagulation in central retinal vein occlusion: A randomised controlled clinical study.

Laatikainen¹,

Kohner²,

Khoury³

et al. 1977

British Journal of Ophthalmology

123

View full text Add to dashboard Cite

SUMMARY A randomised controlled study of photocoagulation compared with no treatment in central retinal vein occlusion is reported. Forty-eight patients were allocated into treated and control groups by a random procedure 3 months after their first visual symptoms. For the analysis they were subdivided into (1) ischaemic type, and (2) hyperpermeability-response macular-oedema type of central retinal vein occlusion.In neither group did treatment confer benefit as far as visual acuity was concerned. However, iris, disc, and retinal neovascularisation improved after treatment in the ischaemic group. In addition none of the treated patients progressed to neovascular glaucoma. Macular-oedema improved in treated patients with the hyperpermeability response, but the visual field was affected and atrophic changes at the macula precluded visual improvement.It is concluded that photocoagulation should be used only to prevent complications in the ischaemic type of central retinal vein occlusion. It does not appear to be of value in the hyperpermeability group.Photocoagulation has been shown to be effective in the treatment of both macular oedema and neovascularisation in diabetic retinopathy. It is therefore reasonable to assume that similar results can be achieved in retinal vein occlusion, where macular oedema and new vessel formation are common complications. There are several reports indicating 'good results' (Zweng et al., 1974;Theodossiadis et al., 1974;Freyler and Nichorlis, 1974;Wetzig and Thatcher, 1974;Oosterhuis and Sedney, 1975;Sedney, 1976) 3 months after initial visual symptoms. At the 3-month examination patients whose visual acuity was 6/24 or worse entered the study provided they did not have neovascular glaucoma or other eye disease affecting vision and precluding treatment, and provided they agreed to randomisation.Randomisation was by the use of pre-prepared sealed envelopes which indicated whether an eye was for treatment by photocoagulation or remained untreated, i.e., control. No other therapy for vein occlusion was given to any of the patients, but glaucoma and medical conditions were treated as required. There were 24 treated and 24 control patients. The mean age of the patients was 62 years (range 44-79 years) in the treated and 61 6 years (range 36-79 years) in the untreated group.The patients were followed up for at least 1 year after entering the trial whenever possible. Five patients were not followed up for the required time. Two died, 4 and 10 months after entering the trial, 1 left the country, and 2 defaulted from follow-up.During the course of the study the initial scheme was slightly modified so that eyes with considerable capillary closure were entered into the trial as soon as the first fluorescein angiogram became available, i.e., before 3 months expired.Prior to analysis patients were subdivided into two subgroups according to the main cause of visual loss as revealed by fluorescein angiography. The 741

show abstract

Section: Discussionsupporting

confidence: 92%

“…No significant improvement in visual acuity in spite of drying out of the macular oedema was found either by Theodossiadis (1976) or May et al (1976).…”

Section: Discussionmentioning

confidence: 77%

Panretinal photocoagulation in central retinal vein occlusion: A randomised controlled clinical study.

Laatikainen¹,

Kohner²,

Khoury³

et al. 1977

British Journal of Ophthalmology

123

View full text Add to dashboard Cite

show abstract

“…These findings have been confirmed120 and others have used panretinal photocoagulation to reverse neovascular glaucoma and rubeosis 9899 108 121 More recently, however, the CRVO study group recommended providing frequent follow up of at risk patients and application of laser when neovascularisation occurs122 because there was no benefit of prophylactic therapy over therapy when complications arise. The follow up recommended was at least monthly and perhaps more in the early stages of the condition.…”

Section: Treatment Of Crvomentioning

confidence: 90%

Central retinal vein occlusion: what's the story?

Williamson

1997

British Journal of Ophthalmology

107

View full text Add to dashboard Cite

Central retinal vein occlusion (CRVO) has been a profitable area of study for many investigators. Shameful then that we still do not understand its pathogenesis or know, definitively, how to treat the condition. Many questions still arise when CRVO is considered. Some of these are outlined in this perspective, hopefully as a guide to future investigation. TerminologyIf confusion over nomenclature is an indicator of confusion over the subject then CRVO is no diVerent. Leibreich in 1854 first described the clinical appearance of CRVO as 'retinal apoplexy' 1 followed closely by Leber in 1877 who preferred 'haemorrhagic retinitis'.2 We now use 'central retinal vein occlusion' assuming the presence of a blockage of the vein in the optic nerve head. Hayreh coined the phrases 'venous stasis retinopathy' for the milder types of CRVO and 'haemorrhagic retinopathy' for the more severe disease.

show abstract

“…Prognosticating this complication has become important, since recent studies (Sedney, 1976;May et al, 1976;Laatikainen, 1977b) have reported that panretinal photocoagulation may be used to reverse or prevent iris neovascularisation after CRVO. It has been suggested, however, that treatment should be completed either early in the course of rubeosis, before extensive peripheral anterior synechiae are established, or prophylactically before clinical rubeosis is recognised.…”

mentioning

confidence: 99%